A Phase II Trial of Erbitux [cetuximab] for Recurrent and Metastatic Mucinous Gastrointestinal Adenocarcinoma Involving the Peritoneal Surfaces.
Phase of Trial: Phase II
Latest Information Update: 31 Oct 2015
At a glance
- Drugs Cetuximab (Primary)
- Indications Gastrointestinal cancer
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 10 Jun 2017 Biomarkers information updated
- 02 Nov 2007 Status change from in progress to completed.
- 22 Oct 2005 New trial record.